Journal
TRANSLATIONAL RESEARCH
Volume 187, Issue -, Pages 93-102Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2017.07.003
Keywords
-
Categories
Funding
- Mustang Bio, Inc.
- Gateway for Cancer Research [R011FD005129-01, R21CA193055]
- Norris Foundation
Ask authors/readers for more resources
Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in the treatment of hematological disease, and its utility for treatment of solid tumors is beginning to unfold. Glioblastoma continues to portend a grim prognosis and immunotherapeutic approaches are being explored as a potential treatment strategy. Identification of appropriate glioma-associated antigens, barriers to cell delivery, and presence of an immunosuppressive microenvironment are factors that make CAR T-cell therapy for glioblastoma particularly challenging. However, insights gained from preclinical studies and ongoing clinical trials indicate that CAR T-cell therapy will continue to evolve and likely become integrated with current therapeutic strategies for malignant glioma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available